Intravacc is an experienced R&D organization with a proven track record in vaccinology of over 100 years. They have a wide range of expertise to independently develop vaccines from lead concept to clinical phase I/II studies as well as their own product pipeline and patents.
Intravacc develops innovative platforms and methods to improve the effectiveness, stability and safety of vaccines.
Intravacc is continuously investing in R&D platforms to facilitate vaccine development. Early development includes vaccine strain design to generate bacterial, viral and cellular seeds for efficient vaccine production.
They also carry out studies on adjuvants and delivery systems, resulting in safe products that are efficacious.
Their successful R&D efforts are then further developed into services they offer to clients.
Intravacc develops bacterial and viral vaccines from discovery to phase II clinical trials. They use their own advanced technologies, such as Vero cell line and the OMV platform.
Intravacc offers assay development and vaccine characterization services. They specialise in immunoassays, molecular biology methods, physicochemical analyses, and biological assays.
Intravacc is one of the leading players in global 3R research (reduce, replace and refine animal experiments).
Intravacc is home to a GMP facility for production of vaccines on pilot scale. This includes a state-of-the-art 100 m2 C/BSL-2 cleanroom.See more